Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans

Acta Pharmacologica Sinica

Volumn 32, Issue 10, 2011, Pages 1285-1293

  Liu, Li ^a   Pan, Xian ^a   Liu, Hai Yan ^b   Liu, Xiao Dong ^a   Yang, Hui Wen ^a   Xie, Lin ^a   Cheng, Jun Lin ^c   Fan, Hong Wei ^c   Xiao, Da Wei ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Shanghai Pharmaceutical Group Co Ltd   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

antofloxacin; CYP1A2; drug interactions; pharmacokinetics; theophylline

Indexed keywords

1 METHYLURIC ACID; 1,3 DIMETHYLURIC ACID; 3 METHYLXANTHINE; ANTOFLOXACIN; CYTOCHROME P450 1A2; QUINOLONE DERIVATIVE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DROWSINESS; DRUG EFFECT; DRUG INDUCED HEADACHE; EXCRETION; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; LIVER MICROSOME; MALE; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; STOMACH DISEASE;

ADULT; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; OFLOXACIN; THEOPHYLLINE; YOUNG ADULT;

EID: 80053910068     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.78     Document Type: Article

References (32)

1. Ye H, Wu JM, Yang YS, Chen KX, Ji RY. Antibacterial activities of the derivatives-YH54 and YH57 of levofloxacin in vitro. Chin Pharmacol Bull 2002; 18: 112-3. (Pubitemid 34259510)
2. Xiao Y, Lu Y, Kang Z, Hou F, Wang S, Li T, et al. Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. Int J Clin Pharmacol Ther 2008; 46: 172-9. (Pubitemid 351493987)
3. Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Zhang M, et al. Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Dispos 2008; 29: 167-72. (Pubitemid 351722161)
4. Gundert-Remy U, Hildebrandt R, Hengen N, Weber E. Non-linear elimination processes of theophylline. Eur J Clin Pharmacol 1983; 24: 71-8. (Pubitemid 13188843)
5. Tang-Liu DD, Williams RL, Riegelman S. Nonlinear theophylline elimination. Clin Pharmacol Ther 1982; 31: 358-69. (Pubitemid 12125457)
6. Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome P450 in human liver microsomes. Drug Metab Dispos 1987; 15: 237-49. (Pubitemid 17056770)
7. Ha HR, Chen J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39: 321-6.
8. Sarkar MA, Hunt C, Guzelian PS, Karnes HT. Characterization of human liver cytochrome P-450 involved in theophylline metabolism. Drug Metab Dispos 1992; 20: 31-7.
9. Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996; 276: 912-7. (Pubitemid 126660562)
10. Bachmann K, White D, Jauregui L, Schwartz JI, Agrawal NG, Mazenko R, et al. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol 2003; 43: 1082-90. (Pubitemid 37174439)
11. Wijnands WJA, Van Herwaarden CLA, Vreeet TB. Enoxacin raises plasma theophylline concentrations. Lancet 1984; 2: 108-9. (Pubitemid 14085159)
12. Edwards DJ, Bowles SK, Svensson CK, Rybak MJ. Inhibition of drug metabolism by quinolone antibiotics. Clin Pharmacokinet 1988; 15: 194-204.
13. Fuhr U, Anders EM, Mahr G, Sörgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992; 36: 942-8.
14. Loi CM, Parker BM, Cusack BJ, Vestal R. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br J Clin Pharmacol 1993; 36: 195-200. (Pubitemid 23275334)
15. Matuschka PR, Vissing RS. Clinafloxacin-theophylline drug interaction. Ann Pharmacother 1995; 29: 378-80.
16. Zhang L, Wei MJ, Zhao CY, Qi HM. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in liver microsomes. Acta Pharmacol Sin 2008; 29: 1507-14.
17. Zhu Q, Liao J, Xie L, Wang GJ, Liu XD. Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica 2009; 39: 293-301.
18. Nie SL, Liu HY, Xie L. Reversed-phase high performance liquid chromatographic method for simultaneous determination of theophylline and its two metabolites in human urine. Chin J Clin Pharmacol Ther 2009; 14: 1386-91.
19. Pang XY, Xie L, Xu X, Liu HY, Liu L, Liu XD. Pharmacokinetics of ATFX in rats coadministered with non-steroidal anti-inflammatory drugs. Chin J New Drugs 2007; 16: 600-3.
20. Kinzig-Schippers M, Fuhr U, Zaigler M, Dammeyer J, Rüsing G, Labedzki A, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther 1999; 65: 262-74. (Pubitemid 29142932)
21. Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000; 28: 1031-7. (Pubitemid 30660356)
22. Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004; 32: 259-66. (Pubitemid 38176944)
23. Fowler S, Zhang H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J 2008; 10: 410-24.
24. Sarkar M, Polk RE, Guzelian PS, Hunt C, Karnes HT. In vitro effect of fluoroquinolones on theophylline metabolism in human liver micro-somes. Antimicrob Agents Chemother 1990; 34: 594-9. (Pubitemid 20122288)
25. Kim EJ, Suh OK, Lee MG. Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. Life Sci 2003; 72: 1231-45. (Pubitemid 36044678)
26. Niki Y, Watanabe S, Yshida K, Miyashita N, Nakajima M, Matsushima T. Effect of pazufloxacin mesilate on the serum concentration of theophylline. J Infect Chemother 2002; 8: 33-6. (Pubitemid 34456577)
27. Niki Y. Pharmacokinetics and safety assessment of tosufloxacin tosilate. J Infect Chemother 2002; 8: 1-18. (Pubitemid 34456574)
28. Fairman DA, Collins C, Chapple S. Progress curves analysis of CYP1A2 inhibition: a more information approach to assessment of mechanism-based inactivation? Drug Metab Dispos 2007; 35: 2159-65. (Pubitemid 350146201)
29. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochromes P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003; 31: 1352-60. (Pubitemid 37310324)
30. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interac tions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-411. (Pubitemid 28477680)
31. Ito K, Iwatsubo T, Kanamitsu S, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003; 31: 945-54. (Pubitemid 36759066)
32. Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Ciprofloxacin-induced theophylline toxicity: a population-based study. Eur J Clin Pharmacol 2011; 67: 521-6.